Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 13, 2006. The report serves to disclose details regarding the appointment of a new Non-Executive Director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance disclosure rather than a financial results report.
Material Changes
There are no material financial changes reported. The primary change is the appointment of Dr. Daniel Podolsky as a Non-Executive Director, effective July 1, 2006.
Management Commentary and Risks
- Director Background: Dr. Podolsky has not served as a director of a publicly quoted company in the past five years.
- Shareholdings: Dr. Podolsky holds no notifiable interests in GlaxoSmithKline plc Ordinary Shares or American Depositary Shares.
- Regulatory Disclosures: No details are required to be disclosed under Paragraph 9.6.13 R (2) to (6) of the Financial Services Authority's Listing Rules.
Investor Verification Points
- Confirm the effective date of Dr. Podolsky's appointment (July 1, 2006).
- Verify the absence of shareholdings or prior directorships for the new appointee as stated.
- Note that this filing contains no financial performance data for the period.